# A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

> **NCT05766410** · PHASE2 · RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Hormone Therapy

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Ribociclib
- **DRUG:** Abemaciclib
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT05766410
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-16
- **Primary completion:** 2025-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05766410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05766410, "A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05766410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*